Microcap Ledger Nuwellis, Inc. $NUWE
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Electromedical & Electrotherapeutic Apparatus
- Headquarters
- Eden Prairie, MN
- Fiscal year end
- December 31
- Shares outstanding
- 3,647,264 [10-Q 2026-08-13]
What the company doesAI summary of filing
Nuwellis develops, manufactures, and commercializes the Aquadex System, a medical device used for ultrafiltration therapy to remove excess fluid from patients with fluid overload who have not responded to diuretic medications. The company sells its products to hospitals and healthcare systems in the United States, generating revenue from three primary clinical markets: pediatrics, critical care, and heart failure. Nuwellis is revenue-generating, with approximately 40% of 2025 revenue from pediatric patients, 32% from critical care patients, and 17% from heart failure patients; the company also faces substantial doubt about its ability to continue as a going concern beyond the second quarter of 2026 without additional capital. [10-K 2026-03-11]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $4.37M | −$9.37M | −$6.29M | $3.92M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $8.27M | −$17.52M | −$10.81M | $1.08M | [10-K 2026-03-11] |
| FY ended Dec 2024 | $8.74M | −$11.16M | −$9.59M | $5.09M | [10-K 2026-03-11] |
- Quarterly cash burn
- −$3.14M
- Cash runway Estimate
- ~3.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 4,373,968 | [10-Q 2024-11-12] |
| 2025-03-07 | 4,373,986 | [10-K 2025-03-11] |
| 2025-05-09 | 4,373,968 | [10-Q 2025-05-13] |
| 2025-08-08 | 902,665 | [10-Q 2025-08-14] |
| 2025-11-07 | 1,658,799 | [10-Q 2025-11-12] |
| 2026-03-06 | 2,310,477 | [10-K 2026-03-11] |
| 2026-05-11 | 2,680,752 | [10-Q 2026-05-15] |
| 2026-08-10 | 3,647,264 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-08-18; declared effective 2026-08-26 [S-3 2026-08-18]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-06-23. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-06-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-23] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-18 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-26 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-26 | 8-K | Regulation FD disclosure |
| 2026-08-18 | S-3 | Registration statement |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-05 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-03 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-08-03 | 424B5 | Prospectus or prospectus supplement |
Alerts for $NUWE
Email me when Nuwellis, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.